Animal studies link HDAC inhibitors with motor recovery after spinal cord injury
A review found frequent reports of improved movement in animal injury models. Unclear study bias and limited evidence on other outcomes leave substantial uncertainty about relevance to human care.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The review reported improved movement outcomes in 30 of 41 animal studies that measured them. These counts describe how often studies reported improvement, without showing the size of recovery. Pain and anxiety were examined much less often. The findings support further preclinical investigation, but they do not establish effectiveness in people with spinal cord injury.
The review judged risk of bias unclear. The abstract gives no pooled effect size, assessment timing or detailed comparison groups, limiting judgments about reliability and how the findings might translate to people.
What was studied
Researchers reviewed drugs called histone deacetylase inhibitors, shortened to HDAC inhibitors. The animal studies used different injury models and several compounds, with valproate appearing most frequently in the review.
Other outcomes had less evidence
Pain and anxiety improved in a single study that assessed them. That narrow evidence base should be kept separate from the more frequently studied movement outcomes when interpreting the review's broad conclusion.
The original publication
The impact of histone deacetylase inhibition on neurobehavioural outcomes in preclinical models of traumatic and non-traumatic spinal cord injury: a systematic review.
Jagodzinska NM, Cole C, Brannigan J et al.
Front Immunol · 2025
- PubMed ID
- 41280930
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.